- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Compugen (CGEN)
Compugen stock price live, this page displays TASE CGEN stock exchange data. View the CGEN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Compugen real time stock price chart below.
What Is the Compugen Stock Price Today?
The Compugen stock price today is 1.610.
What Is the Stock Symbol for Compugen?
The stock symbol for Compugen is "CGEN."
What Stock Exchange Does Compugen Trade On?
Compugen is listed and trades on the Tel Aviv stock exchange.
Is Compugen a Good Stock to Buy?
Determining whether Compugen—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CGEN quote. (ISIN: IL0010852080)
What Is the Compugen Stock Price Today?
The Compugen stock price today is 1.610.
What Is the Stock Symbol for Compugen?
The stock symbol for Compugen is "CGEN."
What Stock Exchange Does Compugen Trade On?
Compugen is listed and trades on the Tel Aviv stock exchange.
Is Compugen a Good Stock to Buy?
Determining whether Compugen—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CGEN quote. (ISIN: IL0010852080)
1.610
-0.040(-2.42%)
Real-time Data
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.590
1.650
52 wk Range
1.350
2.800
CGEN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.5901.650
52 wk Range
1.3502.800
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CGEN Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
4.000
Upside
+148.45%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Valuation implies a strong free cash flow yield
Compugen Company Profile
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company’s pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Compugen Earnings Call Summary for Q4/2024
- Q4 2024 EPS of -$0.07 missed $0.02 forecast; revenue of $1.47M fell short of $11.66M expectation
- 2024 net loss widened to $14.2M; annual revenue decreased 16.7% to $27.9M from $33.5M in 2023
- Cash balance of $103.3M as of Dec 31, 2024; company expects runway into 2027
- Stock near 52-week low of $1.35; premarket drop of 1.11% to $1.79 following earnings release
- Key ovarian cancer study interim results expected in second half of 2026
Last Updated: 2025-03-04, 09:16 a/m
Read Full TranscriptCompare CGEN to Peers and Sector
Metrics to compare | CGEN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCGENPeersSector | |
|---|---|---|---|---|
P/E Ratio | −10.5x | −1.9x | −0.5x | |
PEG Ratio | −0.43 | 0.01 | 0.00 | |
Price/Book | 2.7x | 1.6x | 2.6x | |
Price / LTM Sales | 5.4x | 33.0x | 3.0x | |
Upside (Analyst Target) | 142.4% | 410.7% | 56.4% | |
Fair Value Upside | Unlock | 27.0% | 9.9% | Unlock |
Analyst Ratings
4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 4.000
(+148.45% Upside)
Earnings
Latest Release
Mar 04, 2025
EPS / Forecast
-0.07 / 0.02
Revenue / Forecast
1.47M / 11.66M
People Also Watch
FAQ
What Is the Compugen (CGEN) Stock Price Today?
The Compugen stock price today is 1.61
What Stock Exchange Does Compugen Trade On?
Compugen is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Compugen?
The stock symbol for Compugen is "CGEN."
What Is the Compugen Market Cap?
As of today, Compugen market cap is 151.02M.
What is Compugen Earnings Per Share?
The Compugen EPS is -0.159.
What Is the Next Compugen Earnings Date?
Compugen will release its next earnings report on May 08, 2025.
From a Technical Analysis Perspective, Is CGEN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.